RGEDF (RGEDF) Stock Price & Analysis
RGEDF (RGEDF) fell 19.83% to USD 31 as of June 10, 2026 at 02:38 UTC, according to Nexqual real-time market data.
RGEDF last closed at USD 38.67; the session ranged USD 31–31 on volume of 300 shares. Market capitalization is $5.65B, with a 52-week range of USD 27.17–45.28 (PNK). Source: Nexqual, June 10, 2026 at 02:38 UTC.
Key Statistics (as of June 10, 2026 at 02:38 UTC)
| Price | USD 31 |
|---|---|
| Change | ▼ 19.83% (down) |
| Previous Close | USD 38.67 |
| Open | USD 31 |
| Day Range | USD 31 – 31 |
| 52-Week Range | USD 27.17 – 45.28 |
| Volume | 300 shares |
| Market Cap | $5.65B |
| Exchange | PNK |
Technical Analysis (RGEDF)
Nexqual's technical model rates RGEDF "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:38 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.93 (neutral) |
| vs SMA50 | Below (USD 40.13) |
| MACD | -0.34 (negative) |
Analyst Ratings (RGEDF)
Wall Street analysts rate RGEDF "None", per Nexqual as of June 10, 2026 at 02:38 UTC.
| Consensus Rating | None |
|---|
Earnings (RGEDF)
| Next Earnings Date | 2026-08-07 |
|---|
Source: Nexqual, June 10, 2026 at 02:38 UTC.
Financials & Fundamentals (RGEDF)
| Revenue Growth (YoY) | -1.70% |
|---|---|
| Gross Margin | +67.29% |
| Operating Margin | +0.00% |
| Profit Margin | +24.80% |
| ROE | +16.36% |
| Debt / Equity | 6.86 |
| Current Ratio | 4.69 |
| Free Cash Flow | $193.14B |
Source: Nexqual, June 10, 2026 at 02:38 UTC.
Financial Health Score (RGEDF)
Nexqual rates RGEDF's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 02:38 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 67%, operating 0% |
| Balance Sheet | Strong — Debt/Equity 0.1x |
| Cash Flow | Strong — FCF $193.1B, 21% margin |
| Efficiency | Solid — ROE 16%, ROA 11.0% |
Ownership (RGEDF)
| Insider Ownership | +25.25% |
|---|---|
| Institutional Ownership | +35.63% |
| Shares Outstanding | 182.39M |
| Float | 182.85M |
Source: Nexqual, June 10, 2026 at 02:38 UTC.
Leadership (RGEDF)
RGEDF is led by Gabor Orban (age 46), CEO & Director, per Nexqual as of June 10, 2026 at 02:38 UTC.
| CEO & Director | Gabor Orban (age 46) |
|---|---|
| Group Head of Controlling, CFO & Director | Laszlo Andras Kovacs |
| Human Resources & Technical Director | Katalin Erdei (age 51) |
| Director of Global Regulatory Science, Commerce & Marketing | Tamas Szolyak (age 59) |
Major Backers & Investors (RGEDF)
Notable institutional backers of RGEDF include Fidelity, FINANCIAL INVESTORS TRUST-Seafarer Overseas Growth and Income Fund, Advisors Series Trust-Pzena Emerging Markets Value Fund, according to Nexqual as of June 10, 2026 at 02:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 4.7% |
| FINANCIAL INVESTORS TRUST-Seafarer Overseas Growth and Income Fund | 1.61% |
| Advisors Series Trust-Pzena Emerging Markets Value Fund | 0.79% |
| AIM Investment Fd.s -Invesco Developing Markets Fd. | 0.56% |
| Generali Investments Cee, Investicni Spolecnost, A.s. | 0.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.06% |
| BlackRock | 0.79% |
Source: Nexqual, June 10, 2026 at 02:38 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIOVF | SWEDISH ORPHAN BIOVITRUM AB | USD 47.35 | ▼ 1.35% |
| IPSEY | Ipsen S.A. | USD 42.27 | ▼ 6.15% |
| HKMPF | Hikma Pharmaceuticals plc. | USD 19.07 | ▼ 1.14% |
| QBCRF | Quebecor Inc. | USD 48.87 | ▲ 0.37% |
| HKMPY | Hikma Pharmaceuticals plc. | USD 39.08 | ▼ 0.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:38 UTC. This page is informational and not investment advice.